Navigation Links
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
Date:9/21/2009

ation pathway for OPAXIO."

"We believe focusing on ovarian maintenance, and radiosensitization, not only address areas of unmet medical need, but are in the best long term strategic interest of CTI. With the FDA review of the NDA for pixantrone in relapsed/refractory non-Hodgkin's lymphoma well underway and the phase III Ovarian trial of OPAXIO progressing nicely we are pleased with the advancement and future potential of these novel treatments," said James A. Bianco, M.D., CEO of CTI.

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About OPAXIO

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncol
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... June 08, 2007 /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today ... research project with scientists at Fox,Chase Cancer Center ... Lexicon researchers have discovered a novel and,surprising role ... T lymphocytes. These findings have been published in,the ...
... - NuPathe Inc., a,privately held specialty pharmaceutical ... Phase I study of NP101,SmartRelief, a novel ... NP101 combines NuPathe's SmartRelief(TM) proprietary,iontophoretic transdermal technology ... acute migraine in the United,States. Sumatriptan is ...
Cached Medicine Technology:Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 2Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 3NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Precision Aesthetics is ... years. It was also the first provider of Exilis non-surgical fat reduction in ... after procedures it has attracted a large International clientele. Many patients travel to ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to an ... experts gathered to see if they could reach a consensus on the steps that ... and facelifts. Overall, the group reached 90 percent consensus on a series of steps ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Texas, Feb. 6 Oncology Metrics,a business that ... the treatment of cancer, today announced the launch ... to assist community,oncology practices understand critical operating measures., ... all community-based oncology,practices nationally. Practices of all size ...
... Feb. 6 Cejka Search, a nationally ... announced that,several of its leaders will deliver ... Audio Conference and the American,College of Healthcare ... Audio Conference: Retention Strategies to Keep Top ...
... either alpha-hydroxy acid or beta-hydroxy acid are both highly effective ... the Saint Louis University School of Medicine have found ... acid peels as therapies for the skin disorder. , Peels ... and results that lasted a bit longer than did peels ...
... as cancer cells spread throughout living zebrafish,s body , , ... now get a clearer view into human biology and ... zebrafish, a common model for medical research. , According ... new breed, zebrafish are genetically similar to humans. ...
... asks board member to seek restatement of Beth ... Massbank director Allan,Bufferd should apply the same ... companies to his role on the board of ... group 1199 SEIU United,Healthcare Workers East. Bufferd is ...
... Galaxy Nutritional,Foods (OTC Bulletin Board: GXYF), a leading ... organic and natural food,products, today announced that it will ... the third quarter for the 2008 fiscal year at,11:00 ... plans to report its,operating results before the market opens ...
Cached Medicine News:Health News:Oncology Metrics Launches the National Practice Benchmark: One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operational and Financial Performance 2Health News:Cejka Search Experts Present Latest Developments in Physician Retention and CEO Leadership Skills 2Health News:Treating acne: 2 different acid peels are both effective, study finds 2Health News:Transparent Fish Gives New Window on Disease 2Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
... superb radiation protection-0.62mm (+/- .05)Pb lead glass ... to their level of protection, they are ... smoothly on your bridge while hugging your ... wear corrective lenses, you can order Leaded ...
Medicine Products: